CN102058715A - 一种治疗慢性前列腺炎的中药制剂及其制备方法 - Google Patents
一种治疗慢性前列腺炎的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN102058715A CN102058715A CN 201010595283 CN201010595283A CN102058715A CN 102058715 A CN102058715 A CN 102058715A CN 201010595283 CN201010595283 CN 201010595283 CN 201010595283 A CN201010595283 A CN 201010595283A CN 102058715 A CN102058715 A CN 102058715A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- radix
- herba
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 125
- 238000002360 preparation method Methods 0.000 title claims abstract description 67
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 65
- 208000013507 chronic prostatitis Diseases 0.000 title claims abstract description 46
- 229940079593 drug Drugs 0.000 claims abstract description 39
- 239000000829 suppository Substances 0.000 claims abstract description 22
- 241000218176 Corydalis Species 0.000 claims abstract description 19
- 241000792859 Enema Species 0.000 claims abstract description 11
- 239000007920 enema Substances 0.000 claims abstract description 11
- 229940095399 enema Drugs 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims description 52
- 239000000843 powder Substances 0.000 claims description 40
- 241000628997 Flos Species 0.000 claims description 22
- 238000010438 heat treatment Methods 0.000 claims description 21
- 210000000582 semen Anatomy 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 241001057584 Myrrha Species 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 14
- 235000009508 confectionery Nutrition 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 241000545442 Radix Species 0.000 claims description 6
- 241000207929 Scutellaria Species 0.000 claims description 6
- 235000012907 honey Nutrition 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 239000000645 desinfectant Substances 0.000 claims description 5
- -1 electuary Substances 0.000 claims description 5
- 238000007670 refining Methods 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000011837 pasties Nutrition 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000011505 plaster Substances 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 238000007493 shaping process Methods 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 241001421953 Eclipta <beetle> Species 0.000 claims 3
- 241001529739 Prunella <angiosperm> Species 0.000 claims 3
- 239000008280 blood Substances 0.000 abstract description 103
- 210000004369 blood Anatomy 0.000 abstract description 100
- 210000002307 prostate Anatomy 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 39
- 230000001737 promoting effect Effects 0.000 abstract description 29
- 210000000664 rectum Anatomy 0.000 abstract description 28
- 230000017531 blood circulation Effects 0.000 abstract description 21
- 206010061218 Inflammation Diseases 0.000 abstract description 17
- 230000004054 inflammatory process Effects 0.000 abstract description 16
- 238000006243 chemical reaction Methods 0.000 abstract description 15
- 239000009636 Huang Qi Substances 0.000 abstract description 14
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract description 11
- 210000002808 connective tissue Anatomy 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 7
- 241000411851 herbal medicine Species 0.000 abstract description 7
- 206010020718 hyperplasia Diseases 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 210000004877 mucosa Anatomy 0.000 abstract description 6
- 244000179560 Prunella vulgaris Species 0.000 abstract description 4
- 230000001976 improved effect Effects 0.000 abstract description 4
- 230000003902 lesion Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 240000007371 Cuscuta campestris Species 0.000 abstract 1
- 241000804384 Cynomorium songaricum Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 235000010674 Prunella vulgaris Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 230000008033 biological extinction Effects 0.000 abstract 1
- 230000002390 hyperplastic effect Effects 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 50
- 230000036407 pain Effects 0.000 description 50
- 210000003734 kidney Anatomy 0.000 description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 46
- 201000010099 disease Diseases 0.000 description 44
- 210000004185 liver Anatomy 0.000 description 30
- 210000001015 abdomen Anatomy 0.000 description 24
- 230000007812 deficiency Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 20
- 230000027939 micturition Effects 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 20
- 210000002700 urine Anatomy 0.000 description 19
- 208000033809 Suppuration Diseases 0.000 description 14
- 230000014759 maintenance of location Effects 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 210000000265 leukocyte Anatomy 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 201000001881 impotence Diseases 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 208000011580 syndromic disease Diseases 0.000 description 12
- 206010007247 Carbuncle Diseases 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000004087 circulation Effects 0.000 description 9
- 230000036285 pathological change Effects 0.000 description 9
- 231100000915 pathological change Toxicity 0.000 description 9
- 208000037920 primary disease Diseases 0.000 description 9
- 230000001568 sexual effect Effects 0.000 description 9
- 201000000736 Amenorrhea Diseases 0.000 description 8
- 206010001928 Amenorrhoea Diseases 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 231100000540 amenorrhea Toxicity 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000008506 pathogenesis Effects 0.000 description 8
- 210000004908 prostatic fluid Anatomy 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 206010018691 Granuloma Diseases 0.000 description 7
- 208000019255 Menstrual disease Diseases 0.000 description 7
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 208000031971 Yin Deficiency Diseases 0.000 description 7
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 7
- 229960003321 baicalin Drugs 0.000 description 7
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 206010036596 premature ejaculation Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000003708 urethra Anatomy 0.000 description 7
- 210000001835 viscera Anatomy 0.000 description 7
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 210000000436 anus Anatomy 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 210000003127 knee Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 229940126701 oral medication Drugs 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 210000001550 testis Anatomy 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 210000001113 umbilicus Anatomy 0.000 description 6
- 239000011800 void material Substances 0.000 description 6
- 230000002087 whitening effect Effects 0.000 description 6
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 5
- 206010024419 Libido decreased Diseases 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 208000009205 Tinnitus Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000004856 capillary permeability Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010040872 skin infection Diseases 0.000 description 5
- 231100000886 tinnitus Toxicity 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 208000008967 Enuresis Diseases 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 240000001624 Espostoa lanata Species 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 210000002255 anal canal Anatomy 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000036299 sexual function Effects 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 208000001387 Causalgia Diseases 0.000 description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 244000286838 Eclipta prostrata Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 3
- 208000027744 congestion Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000002640 perineum Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000004680 Rectal Fistula Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 206010047531 Visual acuity reduced Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 206010002156 anal fistula Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000035568 catharsis Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 230000009986 erectile function Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010553 multiple abscesses Diseases 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000007119 pathological manifestation Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 239000009286 sanguis draxonis Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229910052567 struvite Inorganic materials 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000707825 Argyrosomus regius Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000003146 Lobelia chinensis Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036624 Prepuce redundant Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046607 Urine abnormality Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000002533 bulbourethral gland Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004267 spermatic cord Anatomy 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗慢性前列腺炎的中药制剂,其特征在于,所述中药制剂中各种原料药为:熟地黄,锁阳,黄芪,延胡索,淫羊藿,菟丝子,墨旱莲,五味子,白花蛇舌草,红花,制首乌,女贞子,丹参,白芍,没药,夏枯草,蛇床子,败酱草,黄芩,当归,丹皮。本发明采用活血化瘀中草药,能改善毛细血管通透性,减轻炎症反应,促进炎症病灶的消退和吸收,改善结缔组织代谢,既能促进增生病变的转化和吸收,又能使萎缩的结缔组织康复。经直肠给药时,药物可在直肠吸收,灌肠或栓剂能使药物通过直肠黏膜吸收,直达病所,在病变的前列腺内能有较高的浓度,治疗效果较理想,且价格低廉,制备方法简便易行。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物组份的医用配制品及其制备方法,特别涉及一种治疗慢性前列腺炎的中药制剂及其制备方法。
背景技术
1995年12月美国国立卫生研究院(N IH)提出的分类标准将前列腺炎分为I、II、III(包括IIIA和IIIB)、IV类。其中IIIA类为炎症性慢性盆痛综合征,临床较为多见,主要表现为会阴部不适,阴茎、睾丸、小腹疼痛,尿频,尿急,尿痛,尿不尽感及性功能减退等多种症状的综合征。其病因及发病机制目前尚不甚明确,多数学者认为与病原体感染、尿道阻力增高、自身免疫反应、化学因素及神经肌肉因素等有关,其治疗效果也不尽人意。限于当时科学发展水平,诞生于两千多年前的中医学并无前列腺炎的记载,根据临床症状及体征,一般将其归入“淋证”、“精浊”、“白淫”等范畴。中医认为其病因一为嗜食烟、酒、辛辣、肥甘厚味,损伤脾胃,酿生湿热,流注下焦;二为房事不节,直接染毒,湿热毒邪逆行,留驻下焦;三为社会和环境因素,传媒刺激等影响,性欲得不到正常疏泄,频繁手淫,房事不节,忍精不泄,致前列腺反复充血,败精瘀阻精室,蕴久酿毒,阻于经络;或情志不畅,郁怒伤肝,肝气失于疏泄,久则血行不畅而致气血凝滞,气血凝滞又可加重湿热毒邪形成,两者互为因果。慢性前列腺炎的症状因人而异,主要分为以下两种:一种为疼痛症状,含下腹部、腰骶部、肛门周围、会阴部及睾丸、阴茎等部位疼痛;另一种为排尿不适,如尿不尽、尿频、尿急、尿无力、尿滴白等。全身症状主要为焦虑、精力不集中、精神不振,还会伴随有性功能异常,如射精过快、阴茎勃起不坚、性欲低下等。美国国立卫生研究院(NIH)将前列腺炎分为四种类型:I、急性细菌性前列腺炎,II、慢性细菌性前列腺炎,III、慢性非细菌性前列腺炎,IV、无症状性炎症性前列腺炎。其中III型根据前列腺液(EPS)镜检分为两个亚型,WBC(白细胞)10/HP以上为a型,WBC 10/HP以下且pH值较低为b型,即慢性非细菌性前列腺炎/盆底疼痛综合症(CAP/CPPS)。
前列腺炎分急性细菌性、慢性细菌性和非细菌性等不同类型。其发病机理是细菌感染;表皮葡萄球菌免疫反应;关节炎、虹膜炎,尿道器械检查、导尿管放置,上呼吸道、泌尿系感染、性机能变化或饮食不节,喜怒不时引起湿热内蕴、败精浊腐,导致腺体发炎,脓肿。急性期的典型症状是发冷发热、体温升高、恶心呕吐、尿频尿急、尿痛尿浊、便秘、会阴部及下背部胀痛、前列腺肿痛。慢性期的临床表现是头昏头晕、腰部酸痛、尿频尿急、排尿不尽、尿后排出粘液、性欲减退、阳痿早泄、睾丸肿痛前列腺炎病有症状复杂,病程迁延、顽固难愈、容易复发等特点。传统医学应用清利湿热、热毒通淋法多能奏效。慢性前列腺炎是成年男性的常见疾病,据统计该疾病患者占泌尿外科门诊患者的8%~25%,在亚洲20~79岁的男性中前列腺炎患病率为2.7%~8.7%。前列腺特有的解剖结构及慢性前列腺炎的病理特点,使其治疗极为困难。
慢性前列腺炎是男性青壮年的常见病,多发病,在36岁以上的男性中慢性前列腺炎患病率可高达35%~37%。临床上以发病缓慢,病因病理复杂,症状表现多样,体征不典型,病情迁延反复发作,经久难愈为特点。急慢性前列腺炎是指性接触而传染的尿道炎,前列腺炎是男性生殖的常见病,多发生于20岁-40岁的青壮年,本症常见的症状依次为:尿道滴白、腰膝酸软、尿后余沥、小腹胀痛、尿液混浊、头昏头晕、失眠多梦、腰骶胀痛、睾丸及精索胀痛、尿道灼痛、阳痿、早泄等。当前前列腺发病率比较高(在20-45的男性青壮年中,前列腺的发病率达到25-45%以上,在国内泌尿外科门诊中因患急慢性前列腺炎而就诊者也达到25%以上,其中35岁-40岁的发病率可高达40%),致病病原微生物复杂(细菌、病毒、霉菌、滴虫、支原体、衣原体、大肠杆菌、产气杆菌如革兰氏染色阳性球菌-金色葡萄球菌等),一般水溶性抗菌药物由于前列腺位置较深,腺体内血液循环不畅,腺体外包裹三层脂膜、甚至前列腺无菌性炎症等原因很难渗透过前列腺而对前列腺炎症有针对性消除作用,对于前列腺作用微弱、传统口服药物经过胃、肠、肝、胆、肾等吸收消耗及血液循环路途消耗很难在前列腺部位凝聚足够的血药浓度,目前对于慢性前列腺炎的主要治疗方法为药物治疗和物理治疗,其中药物治疗包括各类抗菌素、α受体阻滞剂、免疫抑制剂以及补充锌和维生素,用药途径为内服、注射、直肠灌注、肛门填塞、腺体注射等;其中物理治疗包括微波、肌肉电刺激、热水坐浴、前列腺按摩、双囊四腔导管给药、直接注射(经直肠或会阴)、药物直流电导入。目前的治疗方法中还包括心理治疗,主要以心理疏导为主。但是采用上述的治疗方法,患者较为痛苦,治疗持续时间较长,而且效果不太理想。以上各种办法,要么损伤睾丸生精,要么仅仅为辅助治疗手段,甚至一些方法操作复杂,而且还有不安全、交叉感染等诸多问题,其他肛门直肠给药的栓剂、膏剂存在剂型不合理、配伍不科学、治疗较差的弊端。但大量的临床实践显示上述治疗方法总体效果欠佳。现有技术研究显示,中药在治疗慢性前列腺炎方面已取得了较好的疗效,尤其是在改善患者症状、提高患者生活质量方面具有较明显的优势,且费用较低廉,近年来,有关中药治疗前列腺炎的药物与研究越来越受到本领域研究人员的关注。
发明内容
本发明所要解决的技术问题在于,需要一种价格低廉,毒副作用小,疗效显著,能长期服用的中药制剂来治疗慢性前列腺炎患者;现有技术中治疗前列腺炎的药物,大都是使用抗生素、前列腺包膜内注射,西药毒副作用强,对人体伤害比较大;中药汤剂口服,虽然有一些疗效,但是疗效欠佳,见效慢,且药物生产成本较高,而且制备周期较长,药物吸收率低。
为解决上述技术问题,本发明提供了一种治疗慢性前列腺炎的中药制剂,所述中药制剂中各种原料药的重量份数比为:熟地黄10~20份,锁阳10~20份,黄芪10~20份,延胡索10~20份,淫羊藿10~20份,菟丝子10~20份,墨旱莲10~20份,五味子10~20份,白花蛇舌草10~20份,红花10~20份,制首乌10~20份,女贞子10~20份,丹参10~20份,白芍10~20份,没药10~20份,夏枯草10~20份,蛇床子10~20份,败酱草10~20份,黄芩10~20份,当归10~20份,丹皮10~20份。
所述治疗慢性前列腺炎的中药制剂,各种原料药的重量份数比可以为:熟地黄10~15份,锁阳10~15份,黄芪10~15份,延胡索10~15份,淫羊藿10~15份,菟丝子10~15份,墨旱莲10~15份,五味子10~15份,白花蛇舌草10~15份,红花10~15份,制首乌10~15份,女贞子10~20份,丹参10~20份,白芍10~20份,没药10~20份,夏枯草10~20份,蛇床子10~20份,败酱草10~20份,黄芩10~20份,当归10~20份,丹皮10~20份。
所述治疗慢性前列腺炎的中药制剂,各种原料药的重量份数比优选为:熟地黄10~20份,锁阳10~20份,黄芪10~20份,延胡索10~20份,淫羊藿10~20份,菟丝子10~20份,墨旱莲10~20份,五味子10~20份,白花蛇舌草10~20份,红花10~20份,制首乌10~20份,女贞子10~15份,丹参10~15份,白芍10~15份,没药10~15份,夏枯草10~15份,蛇床子10~15份,败酱草10~15份,黄芩10~15份,当归10~15份,丹皮10~15份。
为解决上述技术问题,本发明还提供了一种治疗慢性前列腺炎的中药制剂的制备方法,所述制剂的剂型为片剂,制备方法包括:
a.将所述原料药混合,切碎,浸泡;
b.将浸泡的原料药加水加热回流提取2次;
c.再取上述水提取后的药渣,加乙醇加热回流提取2次;
d.将上述两种提取液合并,减压回收乙醇并消毒制剂。
所述步骤b中,可以将浸泡好的原料药加热回流提取2次,每次1~2小时,将2次提取液合并静置。
所述步骤c中,可以将上述水提取过的药渣加5~8倍量60~70%乙醇加热回流提取2次,每次1~2小时,将2次提取液合并静置。
所述步骤d中,可以将上述两种提取液合并,减压浓缩相对密度为1.35(80℃)的滤液,回收乙醇,将所得滤液调整比重到1.06,减压得浸膏,用CO 60灭菌,辐照剂量8k,加入淀粉或蔗糖粉制成片剂。
为解决上述技术问题,本发明又提供了一种治疗慢性慢性前列腺炎的中药制剂的制备方法,所述制剂的剂型为蜜炼丸剂,其制备方法包括:先将所述原料药粉碎成粗粉,再进一步粉碎,过120目筛,使能通过120目筛的细粉量在达到30%,收集通过120目筛的细粉得细粉a;再将不能通过120目筛的粗粉投入多功能提取罐提取两次,第一次加8-10倍量水煎煮1-2小时,第二次加4-8倍量水煎煮1-2小时,合并两次煎液,过滤得滤液;加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉b,将a与b混合后调入蜂蜜制成蜜炼丸剂。
为解决上述技术问题,本发明再提供了一种治疗慢性前列腺炎的中药制剂的制备方法,所述制剂的剂型为直肠给药栓剂,其制备方法包括:将基质50℃~60℃加热融化,加入采用权利要求8所述的制备方法制备的细粉a与b,水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,冷却定型制成类弹头状栓剂;所述基质选自:半合成脂肪酸甘油酯、泊洛沙姆、聚乙二醇、羊毛脂中的一种或多种。
所述治疗慢性乙型肝炎的中药制剂的剂型可以为:水煎灌肠剂、片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、丹剂、溶液剂、注射剂、栓剂、硬膏剂、糖浆剂或栓剂。
中药饮片煎剂(灌肠剂):选好原料药,用清水400ml煎为药汤120ml,取上清液凉至药温为40℃左右,嘱患者排便后取侧卧位,用肛管插入肛门约20cm,用50ml注射器吸药液缓慢从肛管灌入(或用输液器输注)直肠行保留灌肠,灌肠后稍垫高臀部平卧30分钟,每天灌肠1次,治疗10天为1疗程。或制成栓剂后用助推器从肛门给药,嘱患者排便后取侧卧位,用助推器加栓剂插入肛门约20cm给药。
经直肠给药时,药物可在直肠吸收50%~70%,且不通过肝脏而直接进入盆腔脏器的3个静脉系统,使前列腺在药物有效浓度作用下迅速康复。从解剖学的角度看,前列腺与直肠的解剖位置相邻,局部有丰富的血管连通,且前列腺周围淋巴网主要在前列腺后方,部分淋巴网与直肠有丰富的交通。因此,中药保留灌肠或栓剂能使药物通过直肠黏膜吸收,直达病所,在病变的前列腺内能有较高的浓度,治疗效果较理想,同时也避免了口服用药和静脉用药的一些不良反应。
本发明采用活血化瘀中草药,能改善毛细血管通透性,减轻炎症反应,促进炎症病灶的消退和吸收,改善结缔组织代谢,既能促进增生病变的转化和吸收,又能使萎缩的结缔组织康复。经直肠给药时,药物可在直肠吸收,且不通过肝脏而直接进入盆腔脏器的3个静脉系统,使前列腺在药物有效浓度作用下迅速康复。灌肠或栓剂能使药物通过直肠黏膜吸收,直达病所,在病变的前列腺内能有较高的浓度,治疗效果较理想,同时也避免了口服用药和静脉用药的一些不良反应。本发明价格低廉,制备方法简便易行,能创造良好的社会效益与经济效益。
具体实施方式
慢性前列腺炎中医称为“白浊”,“精浊”,《素问·调经论》:少阳在泉,客胜,甚则下白尿白。《玉机真藏论》:少腹冤热而病出白。《杂病源流犀烛·五淋二浊源流》:白淫,热郁病也,一名蛊。肾脉贯脊,属肾,络膀胱,故小腹冤热而痛,溲出白液也,据此,则脾受风邪而传于肾,风能煽热,故热邪内结,真精不守,而白物游淫而出。《肾病自疗法·淋浊自疗法·白浊初起之自疗》:小溲之后,渗出精液,如泔如浆,不痛不痒,其名白浊,多属膀胱水道之热所致。前列腺炎在古代并不鲜见,且已经有了较完善的论述,中医认为,其发病原因主要为湿热下行,瘀热阻于下焦,以致精道不利而病,其中医证型以多种多样,但近来有关学者研究发现慢性前列腺炎以湿热型、血瘀型为主,且二证多合并出现,达到了总病例数的78.59%。
慢性前列腺炎属中医“白浊”、“遗精”、“精浊”等范畴。多由于欲念不遂,或房劳过度,致相火妄动,热迫精室,尿道外口有白色分泌物溢出;饮食不节,湿热内蕴,或外感时令疫毒,致湿热蕴结下焦,出现尿频,尿意不尽,久治不愈或治疗不当致湿热瘀血阻滞精道,会阴部,腰骶部。睾丸或小腹隐痛不适。本病为湿热,瘀血阻滞于前阴,精室瘀阻,故治以活血化瘀,清热利湿为治疗原则。现代医学认为,慢性前列腺炎好发于青壮年,在性成熟阶段因过度或频繁的性冲动导致前列腺组织慢性充血与水肿,病理表现为前列腺组织炎症样变,但很少有病原体感染所致的大量炎性细胞浸润。传统医学认为,慢性前列腺炎肾虚型基本病机为肾虚为本,血瘀为辅。灌肠中药针对病机,以补肾活血为治疗原则。慢性前列腺炎时,由于前列腺炎性肥厚,压迫后尿道,引起小便不畅、点滴短少、欲解不得解,影响抗生素渗入炎区发挥作用。现代药理研究证实,活血化瘀药能改善毛细血管通透性,减轻炎症反应,促进炎症病灶的消退和吸收,改善结缔组织代谢,既能促进增生病变的转化和吸收,又能使萎缩的结缔组织康复。经直肠给药时,药物可在直肠吸收50%~70%,且不通过肝脏而直接进入盆腔脏器的3个静脉系统,使前列腺在药物有效浓度作用下迅速康复。从解剖学的角度看,前列腺与直肠的解剖位置相邻,局部有丰富的血管连通,且前列腺周围淋巴网主要在前列腺后方,部分淋巴网与直肠有丰富的交通。因此,中药保留灌肠或栓剂能使药物通过直肠黏膜吸收,直达病所,在病变的前列腺内能有较高的浓度,治疗效果较理想,同时也避免了口服用药和静脉用药的一些不良反应。
我国古代医学将急慢性前列腺炎归属“淋症”范畴。我国传统中医对于前列腺炎早有精辟论述。如清代徐时进渭:“浊者,白粘如精状,从茎中流出,不痛不涩,占下衣有迹者是也。”又说:“精浊者,茎似刀割火灼,而溺窍,病在肝脾;浊出精窍,病在心肾。”临床所见,本病主要病变部位在肾,与膀胱、心脾、肝等也有关,而“精窍”应该是前列腺、精囊腺、尿道球腺等分泌组成精液的组织器官。本病病因错综复杂,总的来说是败精淤浊,湿热下注,精关不固。主要病因是“忍精”和“感染”。前者多由青壮年相火易动,所愿不遂,精不外出,淤于精室;或遗精、手淫、惊恐致,忍精不射,败精流注,遂成浊精。后者多由脾肺素虚,引动下焦湿热;或包皮过长,性交不洁,湿热邪由尿窍上侵,窜于精浊相混,精离其位而成本病。过度饮酒吸烟,嗜食膏粱厚味,亦可湿热内升,下注精室而致本病。概括而言,急慢性前列腺炎在内因上以湿热症,淤血症、中虚症、肾虚症为主要原因和进行症型分类。
本发明以清热解毒,活血化瘀,利尿通淋为治则,本病为湿热,瘀血阻滞于前阴,精室瘀阻,故治以活血化瘀,清热利湿为治疗原则。现代医学认为,慢性前列腺炎好发于青壮年,在性成熟阶段因过度或频繁的性冲动导致前列腺组织慢性充血与水肿,病理表现为前列腺组织炎症样变,但很少有病原体感染所致的大量炎性细胞浸润。传统医学认为,慢性前列腺炎肾虚型基本病机为肾虚为本,血瘀为辅。灌肠中药针对病机,以补肾活血为治疗原则。慢性前列腺炎时,由于前列腺炎性肥厚,压迫后尿道,引起小便不畅、点滴短少、欲解不得解,影响抗生素渗入炎区发挥作用。现代药理研究证实,活血化瘀药能改善毛细血管通透性,减轻炎症反应,促进炎症病灶的消退和吸收,改善结缔组织代谢,既能促进增生病变的转化和吸收,又能使萎缩的结缔组织康复。经直肠给药时,药物可在直肠吸收50%~70%,且不通过肝脏而直接进入盆腔脏器的3个静脉系统,使前列腺在药物有效浓度作用下迅速康复。从解剖学的角度看,前列腺与直肠的解剖位置相邻,局部有丰富的血管连通,且前列腺周围淋巴网主要在前列腺后方,部分淋巴网与直肠有丰富的交通。因此,中药保留灌肠或栓剂能使药物通过直肠黏膜吸收,直达病所,在病变的前列腺内能有较高的浓度,治疗效果较理想,同时也避免了口服用药和静脉用药的一些不良反应。
方中黄芪益气敛阴,助补气生阴之力;当归滋阴润燥、清热除烦;白花蛇舌草、败酱草清热解毒、燥湿敛疮、补脾益肾;白芍载药上行,使药力上行,可行气血,使诸药滋而不腻,补不留瘀;夏枯草消炎化瘀,凉血调和诸药;诸药合用补行兼施,共奏益气滋阴养血,行气活血止痛之功。蛇床子杀菌消炎,黄芩凉血排毒,排脓,敛疮生肌;没药、女贞子、五味子消炎杀菌,活血养肤、清热解毒、生肌长肉的功效,制首乌、锁阳、熟地黄、淫羊藿补肾益精,治疗阳痿早泄、阴衰血竭;气弱阴虚的良药;红花、丹参活血化瘀,丹皮清热;诸药合用有健脾渗湿,清热解毒、燥湿敛疮、生肌长肉的功效,能改善毛细血管通透性,减轻炎症反应,促进炎症病灶的消退和吸收,改善结缔组织代谢,既能促进增生病变的转化和吸收,又能使萎缩的结缔组织康复。
黄芪以补虚为主,能补气固表,利尿托毒,排脓,敛疮生肌。用于气血不足、疮疡内陷、脓成不溃或久溃不敛者。黄芪具有很好的托毒生肌的功能,即久不愈合的脓肿化脓生肌。现代医学研究表明,黄芪内含而多种抗菌有效成分,而且能增强机体的免疫功能,因此还能用于预防某些传染病的发生。《本草逢原》载:“黄芪能补五脏诸虚,治脉弦自汗,泻阴火,去肺热,无汗则发,有汗则止。”是增进抵抗力和防御疾病的良药。
白芍入肝、脾经,养血柔肝,缓中止痛,敛阴收汗。治胸腹胁肋疼痛,泻痢腹痛,自汗盗汗,阴虚发热,月经不调,崩漏,带下,妇人血闭不通,消瘀血,能蚀脓,益女子血。《日华子本草》:治风、补劳,主女人一切病,并产前后诸疾,通月水,退热,除烦,益气,天行热疾,瘟瘴,惊狂,妇人血运,及肠风,泻血,痔瘘。发背,疮疥,头痛,明目,目赤努肉。赤色者多补气,白者治血。
夏枯草微苦,清肝、散结、利尿;治瘟病、乳痈、目痛、黄疸、淋病、高血压等症;治淋巴结核、甲状腺肿大、瘰疬、瘿瘤、乳痈、乳癌、目珠夜痛、羞明流泪、头目眩晕、口眼歪斜、筋骨疼痛、肺结核、急性黄疸型传染性肝炎、血崩、带下。夏枯草为清肝火、散郁结的要药,它所主治的大多是肝经的病症。本品配以菊花、决明子,可清肝明目,治目赤肿痛、配以石决明、钩藤,可平降肝阳,治头痛、头晕;配以玄参、贝母、牡蛎等品,可软坚散结,治瘰历结核。《滇南本草》:祛肝风,行经络,治口眼歪斜。行肝气,开肝郁,止筋骨疼痛、目珠痛,散瘰窃、周身结核。
白花蛇舌草又叫蛇舌草、二叶、竹叶菜、蛇利草。味微苦,甘,寒。入胃、大肠、小肠经,苦寒清热解毒,甘寒清利湿热,对痈肿、咽痛、蛇伤等有较强的解毒消痈作用。一般用于治疗疮毒、咽喉肿痛、肠痈腹痛、毒蛇咬伤,也用于热淋涩痛、小便不利。是拔毒祛湿的良药。
黄芩有清热燥湿,凉血安胎,解毒功效。主治温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾、咳血、目赤、胎动不安、高血压、痈肿疖疮等症。黄芩的临床应用抗菌比黄连还好,而且不产生抗药性。我们借助广谱抗菌作用强的特点,用在真菌培养杂菌感染特厉害,用黄芩提取液效果很好。《本草经疏》:黄芩,其性清肃,所以除邪:味苦所以燥湿;阴寒所以胜热,故主诸热。诸热者,邪热与遍热也,黄疸、肠僻、泄痢,皆湿热胜之病也,析其本,则诸病自瘳矣。苦寒能除湿热,所以小肠利而水自逐,源清则流洁也。血闭者,实热在血分,即热人血室,令人经闭不通,湿热解,则荣气清而自行也。恶疮疽蚀者,血热则留结,而为痈肿渍烂也:火疡者,火气伤血也,凉血除热,则自愈也。黄芩有抗变态反应及抗炎作用:黄芩所含黄芩甙与黄芩素能明显抑制致敏豚鼠离体小肠与离体气管对抗原所产生的过敏性收缩反应,对豚鼠与小鼠的被动全身性变态反应以及豚鼠被动性皮肤变态反应,黄芩甙与黄芩素亦有抑制作用。黄芩有解热作用,多数试验证明,黄芩的有效成份黄芩甙元有解热作用。黄芩有解毒作用,黄芩甙有明显的解毒作用,这可能是由于在β-葡萄糖醛酸甙酶的作用下,黄芩甙分解出葡萄糖醛酸,并与多种毒物结合所致。黄芩甙10毫克能提高士的宁的LD 50达2.5倍,并且使四氯化碳中毒小鼠的肝糖原含量增多。
中药何首乌有生首乌与制首乌之分,直接切片入药为生首乌,用黑豆煮汁拌蒸后晒干入药为制首乌。二者的功用有所不同:生首乌功能解毒、消痈、润肠通便,常用于治疗瘰疬疮痈、风疹瘙痒、肠燥便秘;制首乌功能补肝肾、益精血、乌须发、强筋骨,用于血虚萎黄、眩晕耳鸣、须发早白、腰膝酸软、肢体麻木、崩漏带下、久疟体虚等。本发明所采用的制首乌是补肾益肾的佳品。
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。.《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。
墨旱莲性味甘酸,凉血,止血,补肾,益阴。治吐血,咳血,衄血,尿血,便血,血痢,刀伤出血,须发早白,白喉,淋浊、带下,阴部湿痒。《本草纲目》说它能“乌髭发,益肾阴。”《本草正义》认为旱莲草“入肾补阴而生长毛发。”
菟丝子甘辛平,入肝、肾经。补肾益精,养肝明目,安胎。用于肝肾亏虚,腰膝酸痛,阳痿遗精,尿频遗尿,两目昏暗,胎动不安等症。功能滋补肝肾,固精缩尿,安胎,明目,止泻。用于阳痿遗精、尿有余沥、遗尿尿频、腰膝酸软、目昏耳鸣、肾虚胎漏、胎动不安、脾肾虚泻。
当归,其味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药。大约佐之以补则补,故能养营养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。佐之以攻则通,故能祛痛通便,利筋骨,治拘挛、瘫痪、燥、涩等证。营虚而表不解者,佐以柴、葛、麻、桂等剂,大能散表卫热,而表不敛者,佐以大黄之类,又能固表。惟其气辛而动,故欲其静者当避之,性滑善行,大便不固者当避之。凡阴中火盛者,当归能动血,亦非所宜,阴中阳虚者,当归能养血,乃不可少。
淫羊藿辛、甘、温,归肝、肾经。能补肾助阳,强筋健骨,祛风除湿,善治肾阳不足,阳痿遗精,遗尿尿频;风湿痹痛,骨痿瘫疾。《本草述》云“淫羊火,《本经》药主阴痿绝伤,《日华子》亦首言其疗男子绝阳,女子绝阴,则谓入命门、补真阳者是也。盖命门为肾中之真阳,即人身之元气也,其所谓绝阳绝阴,不本之元气,何以嘘之于既槁。所谓益气力,强志,并治冷气劳气,筋骨挛急等证,皆其助元气之故。老人昏耄,中年健忘,皆元阳衰败而不能上升者也。须知此味以降为升,其升由于能降也。”
熟地黄甘,微温。归肝、肾经。功能主治滋阴补血,益精填髓。用于肝肾阴虚,腰膝酸软,骨蒸潮热,盗汗遗精,内热消渴,血虚萎黄,心悸怔忡,月经不调,崩漏下血,眩晕,耳鸣,须发早白。
蛇床子性辛、苦,温;有小毒。归肾经。主治温肾壮阳,燥湿,祛风,杀虫。用于阳痿,宫冷,寒湿带下,湿痹腰痛;外治外阴湿疹,妇人阴痒;滴虫性阴道炎,是妇科外用良药。《本草经疏》载:蛇床子,味苦平;《别录》辛甘无毒;今详其气味,当必兼温燥,阳也。故主妇人阴中肿痛,男子阴痿湿痒,除痹气,利关节,恶疮。《别录》温中下气,令妇人子服热,男子阴强,令人有子。盖以舌能除湿,温能散寒,辛能润肾,甘能益脾,故能除妇人男子一切虚寒湿所生病。寒湿既除,则病去,性能益阳,故能已疾,而又有补益也。
丹皮味苦,微寒,能清营分、血分实热,有凉血止血之功。治温病热入营血,迫血妄行。归肝经。功能主治清热凉血,散瘀止痛。用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡。丹皮清热凉血的作用较佳,既能清血分实热,又能治阴虚发热。《本经》载其:“主寒热,中风契从、痉、惊痫邪气,除坚症瘀血留舍肠胃,安五脏,疗痈疮。
五味子温;酸、甘;归肺、心、肾经;收敛固涩,益气生津,补肾宁心。用于久嗽虚喘,梦遗滑精,遗尿尿频,久泻不止,自汗,盗汗,津伤口渴,短气脉虚,内热消渴,心悸失眠。《本草经疏》载:五味子主益气者,肺主诸气,酸能收,正入肺补肺,故益气也。其主咳逆上气者,气虚则上壅而不归元,酸以收之,摄气归元,则咳逆上气自除矣。劳伤赢瘦,补不足,强阴,益男子精。《别录》养五脏,除热,生阴中肌者,五味子专补肾,兼补五脏,肾藏精,精盛则阴强,收摄则真气归元,而丹田暖,腐熟水谷,蒸糟粕而化精微,则精自生,精生则阴长,故主如上诸疾也。
女贞子用于肝肾阴虚的目暗不明,视力减退,须发早白,腰酸耳鸣及阴虚发热等。本品能补肝肾阴,但药力平和,须缓慢取效。治目暗不明,常配熟地,枸杞等同用,治须发早白,常配桑葚同用,阴虚发热,常配地骨皮。肝肾阴虚,头昏目眩、遗精耳鸣、腰膝酸软,须发早白,冠心病、高脂血症、高血压、慢性肝炎。对肝脏的保护作用研究认为,女贞子含有齐墩果酸,给大鼠皮下注射,可降低血清谷丙转氨酶,对四氯化碳诱发的肝损伤有明显保护作用,并能促进肝细胞再生.齐墩果酸亦可使肝内甘油三酯蓄积减少、肝细胞变性坏死明显减轻、糖原蓄积增加、血清γ球蛋白下降;超微结构可见肝细胞内线粒体肿胀与内质网囊泡变性减轻、肝组织间质炎症反应减弱。
红花性温,味辛。主治活血通径、散瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤。《本草汇言》:红花,破血、行血、和血、调血之药也。主胎产百病因血为患,或血烦血晕,神昏不语;或恶露抢心,脐腹绞痛;或沥浆难生,;或胞衣不落,子死腹中,是皆临产诸证,非红花不能治。若产后血晕、口噤指搦;或邪入血室,谵语发狂;或血闷内胀,僵仆如死,是皆产后诸证,非红花不能定。凡如经闭不通而寒热交作,或过期腹痛而紫黑淋漓,或跌扑损伤而气血瘀积,或疮疡痛痒而肿溃不安,是皆气血不和之证,非红花不能调。《药品化义》:红花,善通利经脉,为血中气药,能泻而又能补,各有妙义。若多用三、四钱,则过于辛温,使血走散。同苏木逐瘀血,合肉桂通经闭,佐归、芍治遍身或胸腹血气刺痛,此其行导而活血也。若少用七、八分,以疏肝气,以助血海,大补血虚,此其调畅而和血也;若止用二、三分,入心以配心血,解散心经邪火,令血调和,此其滋养而生血也;分量多寡之义,岂浅鲜哉。
败酱草性味苦平,具有清热解毒、排脓破瘀的功效。能医肠痈、下痢、赤白带下、产后瘀滞腹痛、目赤肿痛。入胃、大肠、肝经。主治清热解毒,消痈排脓,活血行瘀。用于肠痈、肺痈及疮痈肿毒,实热瘀滞所致的胸腹疼痛,产后瘀滞腹痛等症。
没药散血去瘀,消肿定痛。主治跌打损伤、金疮、筋骨、心腹诸痛、症瘕、经闭、痈疽肿痛、痔漏、目障。味苦,辛,平。入肝、脾、心、肾经。《本草经疏》载其:“凡骨节痛与夫胸腹胁肋痛,非瘀血停留而因于血虚者不宜用。产后恶露去多,腹中虚痛者不宜用。痈疽已溃不宜用。目赤肤翳非血热甚者不宜用。”配乳香,活血散瘀、行气舒筋。
锁阳味甘,性温。能补肾阳,益精血,润肠通便。能提高免疫系统抵抗力;清除自由基;抗血小板聚集;具有糖类皮质激素样作用。临床用锁阳主治:阳痿早泄、阴衰血竭;气弱阴虚,大便燥结、小便频数,血尿,淋漓不尽;腰膝酸软、疲乏无力;畏寒俱冷,四肢疼痛;月经不调,宫冷带下;女子不孕,男子不育;失眠健忘,脱发早白,胃酸溃疡等等。最新医学研究发现:锁阳能够促进人体细胞再生和新陈代谢,增强免疫调节能力,具有明显的防癌、抗病毒和延缓衰老作用。近年来,用锁阳治疗前列腺肥大和增生、治疗白血病、治疗糖尿病、治疗哮喘、治疗早泄都取得了很好的效果。
延胡索为罂粟科多年生草本植物延胡索的决茎。其味辛、苦,性温,归心、肝、脾经。有活血、行气、止痛之功效。为活血、利气、止痛之良药。延胡索始载《开宝本草》,言其“主破血,产后诸病因血为者;妇人月经不调,腹中结块,崩中淋露,产后血运,暴血冲上,因损下血。或酒摩及煮服”。《汤液本草》言其“治心气小腹痛,有神”。《本草纲目》言其“活血利气,止痛,通小便”,“能行血中气滞,气中血滞。故专治一身上下诸痛”,“心痛欲死,速觅延胡”。
本发明蜜丸剂的制作过程为:将熟地黄1000g,锁阳1000g,黄芪1000g,延胡索1000g,淫羊藿1000g,菟丝子1000g,墨旱莲1000g,五味子1000g,白花蛇舌草1000g,红花1000g,制首乌1000g,女贞子1000g,丹参1000g,白芍1000g,没药1000g,夏枯草1000g,蛇床子1000g,败酱草1000g,黄芩1000g,当归1000g,丹皮1000g混合,先将所述原料药粉碎成粗粉,再进一步粉碎,过120目筛,使能通过120目筛的细粉量在达到30%,收集通过120目筛的细粉得细粉a;再将不能通过120目筛的粗粉投入多功能提取罐提取两次,第一次加8-10倍量水煎煮1-2小时,第二次加4-8倍量水煎煮1-2小时,合并两次煎液,过滤得滤液;加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉b,将a与b混合后调入蜂蜜制成蜜炼丸剂。
本发明片剂的制作过程为:将熟地黄1000g,锁阳1000g,黄芪1000g,延胡索1000g,淫羊藿1000g,菟丝子1000g,墨旱莲1000g,五味子1000g,白花蛇舌草1000g,红花1000g,制首乌1000g,女贞子1000g,丹参1000g,白芍1000g,没药1000g,夏枯草1000g,蛇床子1000g,败酱草1000g,黄芩1000g,当归1000g,丹皮1000g混合,切碎,浸泡。将浸泡好的原料药加热回流提取2次,每次1~2小时,将2次提取液合并静置。再将上述水提取过的药渣加5~8倍量60~70%乙醇加热回流提取2次,每次1~2小时,将2次提取液合并静置。将上述两种提取液合并,减压浓缩相对密度为1.35(80℃)的滤液,回收乙醇,将所得滤液调整比重到1.06,减压得浸膏,用CO 60灭菌,辐照剂量8k,加入淀粉或蔗糖粉制成片剂。可以每24片为一板。
本发明胶囊剂的制备方法包括:取熟地黄1000g,锁阳1000g,黄芪1000g,延胡索1000g,淫羊藿1000g,菟丝子1000g,墨旱莲1000g,五味子1000g,白花蛇舌草1000g,红花1000g,制首乌1000g,女贞子1000g,丹参1000g,白芍1000g,没药1000g,夏枯草1000g,蛇床子1000g,败酱草1000g,黄芩1000g,当归1000g,丹皮1000g混合,所述组份按配比混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温下,与乙醇共同浸渍10~20天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液,加热浓缩至糊状加糊精混合,制粒。
本发明直肠给药栓剂的制备方法包括:将熟地黄1000g,锁阳1000g,黄芪1000g,延胡索1000g,淫羊藿1000g,菟丝子1000g,墨旱莲1000g,五味子1000g,白花蛇舌草1000g,红花1000g,制首乌1000g,女贞子1000g,丹参1000g,白芍1000g,没药1000g,夏枯草1000g,蛇床子1000g,败酱草1000g,黄芩1000g,当归1000g,丹皮1000g混合加入5-10倍量的水浸泡1-2小时,提取2次;加热提取1-2小时,浓缩至浸膏状,成为组份1;剩余药渣加60-90%乙醇浸泡0.5-1.5小时,提取两次,每次1-2小时,合并提取液,滤过,浓缩,80-160目滤过,6000-10000转/分钟离心后的上清液,经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为1.35(80℃)的浸膏,加热回流提取2次,每次30分钟~45分钟,提取活性成份,将2次提取液合并静置成浸膏状,作为组份2。然后取基质加热融化,温度50℃~60℃,加入组份1和组份2,也可使用蜜炼丸剂制备方法中得到的细粉a+b;水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,插入棉栓,冷却定型制成类似子弹头状栓剂;一般所用基质可为:半合成脂肪酸甘油酯、羊毛脂、聚乙二醇,药细粉与基质的配比为1∶2~1∶4,优选为1∶3;或采用泊洛沙姆poloxamer作为基质,比其他基质的溶解度柔和、快速,载药量也较高。
中药饮片煎剂(灌肠剂):按辨证选用对症方,用清水400ml煎为药汤120ml,取上清液凉至药温为40℃左右,嘱患者排便后取侧卧位,用肛管插入肛门约20cm,用50ml注射器吸药液缓慢从肛管灌入(或用输液器输注)直肠行保留灌肠,灌肠后稍垫高臀部平卧30分钟,每天灌肠1次,治疗10天为1疗程。或制成栓剂后用助推器从肛门给药,嘱患者排便后取侧卧位,用助推器加栓剂插入肛门约20cm给药。
经直肠给药时,药物可在直肠吸收50%~70%,且不通过肝脏而直接进入盆腔脏器的3个静脉系统,使前列腺在药物有效浓度作用下迅速康复。从解剖学的角度看,前列腺与直肠的解剖位置相邻,局部有丰富的血管连通,且前列腺周围淋巴网主要在前列腺后方,部分淋巴网与直肠有丰富的交通。因此,中药保留灌肠或栓剂能使药物通过直肠黏膜吸收,直达病所,在病变的前列腺内能有较高的浓度,治疗效果较理想,同时也避免了口服用药和静脉用药的一些不良反应。
药理学毒性试验
一、抗菌实验
体内抗菌试验结果表明,本发明对大肠杆菌和变形杆菌的动物有明显的保护作用,可减病情的发展,降低动物的死亡率;体外抗菌实验结果表明,前列泌尿栓对泌尿系统感染的细菌有不同程度的抑菌和杀菌作用;对实验性大鼠前列腺炎的影响实验结果表明,本发明可抑制细菌感染后前列腺腺体的增重,减缓病情的发展,抑制前列腺组织的病理形态变化;给药后2-5小时可以使动物的尿量明显增加;对新鲜酵母引起的家兔体温升高给药后5小时明显的降温作用;对二甲苯引起的动物耳壳肿胀及对棉球肉芽肿组织有明显的抑制作用,并抑制毛细血管通透性的增加;对化学物质刺激动物腹膜或温度刺激动物体表引起的疼痛有一定的抑制作用。
二、动物急性毒性试验研究:
当本发明采用直肠给药途径,测得小鼠的一日最大给药量为62.7g/kg(以药粉计),约为拟临床人用量的1567.5倍(人以60kg计),大鼠的一日最大给药量62.7g/kg(以药粉计),约为拟临床人用量的1567.5倍。实验动物均连续观察一周,其外观体征、精神状态、饮食、饮水、粪便等均未见明显异常。实验结束时,动物均健康存活,体重增加。
三、动物长期毒性试验研究:
本试验设本发明药物高、中、低剂量组和基质对照组、空白对照组,采用直肠给药途径给予大鼠,给药剂量分别为3.2、2.4和1.6g/kg(以药粉计),相当于拟临床病人用量[0.04g(药粉)/kg]的80、60和40倍,连续给药2个月,在给药过程中,各给药组及基质组大鼠的体重、饮食量、外观体征、行为活动、精神状态、毛色、粪便性状与空白对照组比较,无明显差异(P>0.05),动物体重增长值和主要脏器系数与空白对照组比较差异不显著(P>0.05),血液学和血液生化指标检查结果给药组个别指标与空白对照组比较差异显著(P<0.05),但恢复期结束后有差异的血液学和血液生化指标均已恢复正常,其他指标与空白对照比较差异不显著(P>0.05),给药期和恢复期组织学检查高剂量组动物主要脏器与空白对照组比较未见明显差异,未见迟缓性毒性出现。
四、动物局部刺激试验:
本发明栓剂的豚鼠皮肤过敏试验和大鼠直肠用药刺激性试验。结果表明:皮肤过敏试验,高剂量组0.8g(药粉)/kg、低剂量组0.1g(药粉)/kg,分别相当于拟临床人用量[0.04g(药粉)/kg]的20倍、2.5倍,经皮肤给药,均未见动物产生变态反应;直肠用药刺激性试验高剂量组5.0g(药粉)/kg,低剂量组3.2g(药粉)/kg,分别相当于拟临床人用量的125、80倍,在规定的时间内观察直肠粘膜均无充血、水肿等现象,病理组织学检查与空白对照组比较无明显差异,未见出现明显的刺激性反应,每组留存的部分动物其全身状况,体重、呼吸、循环、中枢神经系统及四肢活动等,均无明显异常反应。
药理学实验说明:
1.试验目的:观察连续给予受试物一周,对大鼠棉球肉芽肿增生的抑制作用对昆明小鼠疼痛的抑制作用。
2.受试物
本发明中药片剂;动物由山东大学实验动物中心提供的SD大鼠,鼠龄4个月,体重:试验体重366±24(X±SD)g。性别:雄性;每组动物数:各10只;饲养条件:清洁级动物房,温度22±2℃,湿度45±10%,换气次数12次/分,喂养本中心常规消毒大鼠饲料,饮用消毒水,群居饲养,每笼5只。剂量设置及理由:参照新药药理学指导原则,医院提供的临床拟用剂量,即成人2.25g/d,按60kg体重计算,2.25g/d÷60kg体重:0.0375g/kg/d。动物给药量按临床拟用量的2.5倍、5倍、10倍设小、中、大三个剂量组。(1)小剂量组,0.0375g/kgx2.5倍=0.09375g/kg/d;(2)中剂量组,0.0375g/kgx5倍=0.1875g/kg/d,(3)大剂量组0.0375g/kgx10倍=0.375g/kg/d。
3.对照组
a.空白对照组:给予相同体积的消毒饮用水;b.阿司匹林组:200mg/kg;c.前列康组:相当于临床口服剂量的5倍。成人5g/d,按60kg计算,即5g÷60kgx5倍=0.417g/kg/d;给药体积每只大鼠给药容量10ml/kg,按等量不同给药浓度,给药途经灌胃与临床给药途径相同。药物及材料:阿司匹林,上海九福药业有限公司,批号001201,规格:25mg/片临床用量,25-50mg/日,口服。避光、密封保存。前列康,康恩贝集团制药有限公司制造,批号000421-1,规格0.5gx60片/瓶,临床用量,一次3-4片,一日3次,口服。脱脂棉球,做成重10±1g,大小相近,直径约7mm,高压消毒后使用。
4.试验方法
4.1药物配制:取本发明片剂3.75g,溶于100ml饮用水中,配置成3.75%浓度为高剂量组,中剂量组、小剂量组分别稀释2倍、4倍。取阿司匹林2g,溶于100ml消毒饮用水中,配置成2%的浓度,取前列康4.17g,溶于100ml饮用水中,配置成4.17%的浓度。
4.2动物模型:大鼠在戊巴比妥麻醉下,在左右掖窝各剪一小口,用血管钳扩充皮下组织,将灭菌棉球分别植入大鼠两侧掖窝皮下,然后缝合,术后次日开始按上述剂量给药,第8天称重,给药2小时后,将大鼠麻醉,剥离并取出棉球肉芽组织,剔尽周围脂肪组织,60℃下12h,烘干,称重。
4.3观察指标肉芽肿净重,将烘干的肉芽肿重量减去原棉球重量即为肉芽肿净重。
4.4统计学方法采用OFFICE软件,算出每100g体重下棉球的重量(各组肉芽肿的指数),计算其平均值和标准差(X±SD),再进行显著性t检验。
5.结果及评价,结果如下表。
本发明片剂对大鼠棉球肉芽肿增生的影响
结果表明:本发明片剂各剂量组与阿司匹林组、前列康组均有抑制慢性肉芽肿增生,且本发明片剂效果较为理想。
临床资料
1.1诊断及纳入标准
诊断参照卫生部颁布的《中药新药临床研究指导原则》及美国国立卫生研究院慢性前列腺炎症状积分指数(N IH2CPSI)评分标准。基本诊断标准为前列腺按摩液(EPS)常规镜检白细胞(WBC)>10个/HP、细菌培养阴性,另外有下列3项中的2项:①尿路刺激症状:尿频、尿急、尿痛、尿不尽、尿道滴白;②疼痛症状:腰骶、会阴、小腹、睾丸等部位疼痛或不适;③性功能异常:早泄、阴茎勃起功能障碍、性欲减退。
1.2排除标准 ①神经原性膀胱炎、膀胱肿瘤、膀胱结石、前列腺癌等患者及有前列腺手术史者;②肝肾功能异常者;③两周内采用其他治疗前列腺疾病的药物,包括抗生素、受体阻滞剂、中药制剂等。
1.3一般资料 所有病例来源于自2006年3月~2009年12月来本院生殖医学科的就诊患者。随机分为两组,治疗组68例,年龄21~48岁,病程7个月~10年;对照组52例,年龄19~52岁,病程8个月~12年。两组患者年龄、病程经比较差异均无统计学意义(P>0.05),具有可比性。
2治疗方法
2.1治疗组 服用自拟中药汤剂每日1剂,连续水煎2次,两次滤液相混合约400ml,200ml/次早晚温服。连续服用1个月。
2.2对照组 口服前列康片(浙江康恩贝有限公司生产),每次3片,每日3次,疗程为1个月。两组治疗前后均进行N IH2CPSI评估、前列腺液及肝、肾功能和血、尿常规检查。
3治疗结果
参照《中药新药临床研究指导原则》及美国国立卫生研究院慢性前列腺炎症状积分指数(N IH2CPSI)的评分及EPS中WBC计数作为疗效判定的标准。治愈:N IH2CPSI评分减少95%以上,EPS镜检连续两次正常;显效:NIH2CPSI评分减少60%~94%,EPS镜检WBC减少≥60%;有效:NIH2CPSI评分减少30%~59%,EPS镜检WBC减少≥30%;无效:NIH2CPSI评分减少<30%,EPS镜检WBC减少<30%。两组治疗结果见表1,治疗组总有效率为86.8%,对照组总有效率为71.2%,两组总有效率比较,差异有显著性(χ2=4.488,P<0.05)。
表1 两组治疗结果的比较(%)
组别 | 例数(n) | 治愈 | 显效 | 有效 | 无效 |
对照组 | 52 | 12(23.1) | 13(25) | 12(23.1) | 15(28.8) |
治疗组 | 68 | 20(29.4) | 21(30.9) | 18(26.5) | 9(13.2) |
注:总有效率=治愈率+显效率+有效率,两组总有效率比较,P<0.05
两组症状的疗效比较见表2,治疗组在改善患者会阴不适、小腹痛、阴茎痛、睾丸痛、阴茎勃起功能方面明显优于对照组(经χ2检验,P<0.05);对改善患者尿频、尿不尽感方面两组比较差异无显著性(经χ2检验,P>0.05)。所有患者服药后均未有明显不良反应。治疗前后血、尿常规及肝、肾功能无异常。
表2 两组常见症状的疗效比较
注:P<0.05
4讨论
慢性前列腺炎是泌尿男科最常见疾病之一,给患者带来躯体痛苦和心理障碍,虽治疗方法多种多样,但疗效有限,常常困扰着患者和医生。随着近20年来研究的不断深入,逐渐认识到慢性前列腺炎不是一种单纯的疾病,而是具有各自特异表现的一类综合征。本病病位在下焦膀胱及精室,湿热、气滞、血瘀日久耗伤正气。因此,本病病机关键为湿热、气滞、血瘀和气虚。综合有关本病的大量文献,不论是辨证施治,还是专方加减,在中医理、法层面的基本判断上是相似的。目前慢性前列腺炎的疗效不显著,其根本原因在于病因多样、病机复杂。但从临床上看,在改善症状、降低费用、彻底治愈等方面,中医药具有其自身的优势。
具体实施方式:
具体实施例1:金某,男,47岁,2008年4月8日初诊。患者诉5年来常觉会阴部、下腹隐痛不舒,经直肠指检及前列腺液化验,诊断为慢性前列腺炎,曾多次使用红霉素、百炎净等抗菌药物,治疗效果不理想,近半年来病情加重,且伴性功能减退。刻诊:会阴部及下腹隐痛不适,排尿后和便后常有白色分泌物自尿道口流出,性功能减退,头昏、头胀、乏力、疲惫,舌质红、少苔、根黄腻,脉细弦。前列腺液化验:红细胞(+),白细胞(++),脓细胞少量。直肠指检:前列腺肥大、疼痛。证属本虚标实,其虚在肾,其实责之湿浊下注,治宜补肾导浊为主。药用:熟地黄10g,锁阳15g,黄芪10g,延胡索10g,淫羊藿15g,菟丝子15g,墨旱莲10g,五味子10g,白花蛇舌草15g,红花10g,制首乌15g,女贞子10g,丹参10g,白芍10g,没药10g,夏枯草15g,蛇床子10g,败酱草10g,黄芩10g,当归10g,丹皮15g。上药用清水煎至500ml,用消毒纱布过滤后,装入输液瓶中备用。具体用法:用输液管连接输液瓶,其末端接无菌导尿管并涂石蜡油,将患者臀部垫高,导尿管插入直肠约15cm,药液温度保持35~40℃,以60~80滴/min速度,缓慢滴入。10天为1个疗程,疗程之间间隔5天,3个疗程结束后,上述症状缓解,复查前列腺液,正常,临床治愈。
具体实施例2:谢某,男,36岁,患慢性前列腺炎、前列腺肥大,症状为尿线细、排尿困难、尿道口灼痛,并有性欲低下、阳痿等症状,严重影响睡眠。经多方诊治效果不佳。经检查前列腺液,白细胞16个/HP(镜下高倍视野)红细胞(-)。药用:熟地黄15g,锁阳10g,黄芪15g,延胡索10g,淫羊藿10g,菟丝子15g,墨旱莲10g,五味子15g,白花蛇舌草10g,红花10g,制首乌15g,女贞子10g,丹参10g,白芍10g,没药15g,夏枯草15g,蛇床子10g,败酱草10g,黄芩10g,当归10g,丹皮10g。服用本发明实施例所述的片剂15天症状缓解减轻,又继续服用2个月阴部有凉爽感觉,下腹不胀,潮湿现象消失,身体恢复正常,至今没有复发。
具体实施例3:李某,男,49岁,近1年来,小便余沥不尽,欲尿无畅易感,夜间尿频为甚,病情反复发作达5年之久,且有性功能严重下降、早泄严重,并有烦燥、失眠等症状,经诊断为慢性前列腺炎及前列腺增生。前列腺液化验:红细胞(+),白细胞(++),脓细胞少量。直肠指检:前列腺肥大、疼痛。证属本虚标实,其虚在肾,其实责之湿浊下注,治宜补肾导浊为主。药用:熟地黄10g,锁阳10g,黄芪15g,延胡索10g,淫羊藿10g,菟丝子15g,墨旱莲10g,五味子15g,白花蛇舌草10g,红花10g,制首乌15g,女贞子15g,丹参10g,白芍10g,没药10g,夏枯草15g,蛇床子10g,败酱草10g,黄芩10g,当归10g,丹皮15g。服用本发明实施例所述的蜜炼丸剂20天后疗程后,下腹不胀,潮湿现象消失,尿频改善,继续服用4个月,上述症状消失,身体恢复正常,至今无复发。
具体实施例4:兰某,28岁,自述尿频、尿道口灼痛,并有性欲低下、阳痿等症状,青春期手淫过度。检查发现会阴部及下腹隐痛不适,排尿后和便后常有白色分泌物自尿道口流出,性功能减退,头胀、乏力、疲惫,舌质红、少苔、根黄腻,脉细弦。前列腺液化验:红细胞(+),白细胞(++),脓细胞少量。直肠指检:前列腺肥大、疼痛。证属本虚标实,其虚在肾,其实责之湿浊下注,治宜补肾导浊为主。药用:熟地黄15g,锁阳15g,黄芪15g,延胡索10g,淫羊藿10g,菟丝子15g,墨旱莲10g,五味子15g,白花蛇舌草15g,红花10g,制首乌15g,女贞子15g,丹参10g,白芍10g,没药10g,夏枯草15g,蛇床子10g,败酱草10g,黄芩10g,当归10g,丹皮15g。服用本发明实施例所述的蜜炼丸剂15天后,尿频改善,下腹不胀,潮湿现象消失,继续服用2个月,上述症状消失,身体恢复正常,至今无复发。
Claims (10)
1.一种治疗慢性前列腺炎的中药制剂,其特征在于,所述中药制剂中各种原料药的重量份数比为:熟地黄10~20份,锁阳10~20份,黄芪10~20份,延胡索10~20份,淫羊藿10~20份,菟丝子10~20份,墨旱莲10~20份,五味子10~20份,白花蛇舌草10~20份,红花10~20份,制首乌10~20份,女贞子10~20份,丹参10~20份,白芍10~20份,没药10~20份,夏枯草10~20份,蛇床子10~20份,败酱草10~20份,黄芩10~20份,当归10~20份,丹皮10~20份。
2.根据权利要求1所述治疗慢性前列腺炎的中药制剂,其特征在于,所述中药制剂中各种原料药的重量份数比为:熟地黄10~15份,锁阳10~15份,黄芪10~15份,延胡索10~15份,淫羊藿10~15份,菟丝子10~15份,墨旱莲10~15份,五味子10~15份,白花蛇舌草10~15份,红花10~15份,制首乌10~15份,女贞子10~20份,丹参10~20份,白芍10~20份,没药10~20份,夏枯草10~20份,蛇床子10~20份,败酱草10~20份,黄芩10~20份,当归10~20份,丹皮10~20份。
3.根据权利要求1所述治疗慢性前列腺炎的中药制剂,其特征在于,所述中药制剂中各种原料药的重量份数比为:熟地黄10~20份,锁阳10~20份,黄芪10~20份,延胡索10~20份,淫羊藿10~20份,菟丝子10~20份,墨旱莲10~20份,五味子10~20份,白花蛇舌草10~20份,红花10~20份,制首乌10~20份,女贞子10~15份,丹参10~15份,白芍10~15份,没药10~15份,夏枯草10~15份,蛇床子10~15份,败酱草10~15份,黄芩10~15份,当归10~15份,丹皮10~15份。
4.一种如权利要求1~3中任一项所述治疗慢性前列腺炎的中药制剂的制备方法,其特征在于,所述制剂的剂型为片剂,制备方法包括:
a.将所述原料药混合,切碎,浸泡;
b.将浸泡的原料药加水加热回流提取2次;
c.再取上述水提取后的药渣,加乙醇加热回流提取2次;
d.将上述两种提取液合并,减压回收乙醇并消毒制剂。
5.根据权利要求4所述制备方法,其特征在于,所述步骤b中将浸泡好的原料药加热回流提取2次,每次1~2小时,将2次提取液合并静置。
6.根据权利要求4或5所述制备方法,其特征在于,所述步骤c中,将上述水提取过的药渣加5~8倍重量份的60~70%乙醇加热回流提取2次,每次1~2小时,将2次提取液合并静置。
7.根据权利要求4~6中任一项所述制备方法,其特征在于,所述步骤d中,将上述两种提取液合并,减压浓缩为80℃时相对密度1.35的滤液,回收乙醇,将所得滤液调整比重到1.06,减压得浸膏,用CO 60灭菌,辐照剂量8k,加入淀粉或蔗糖粉制成片剂。
8.一种如权利要求1~3中任一项所述治疗慢性前列腺炎的中药制剂的制备方法,其特征在于,所述制剂的剂型为蜜炼丸剂,其制备方法包括:先将所述原料药粉碎成粗粉,再进一步粉碎,过120目筛,使能通过120目筛的细粉量在达到30%,收集通过120目筛的细粉得细粉a;再将不能通过120目筛的粗粉投入多功能提取罐提取两次:第一次加8-10倍重量份的水煎煮1-2小时,第二次加4-8倍重量份的水煎煮1-2小时;合并两次煎液,过滤,加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉b,将细粉a与细粉b混合后调入蜂蜜制成蜜炼丸剂。
9.一种如权利要求1~3中任一项所述治疗慢性前列腺炎的中药制剂的制备方法,其特征在于,所述制剂的剂型为直肠给药栓剂,其制备方法包括:将基质50℃~60℃加热融化,加入采用权利要求8所述的制备方法制备的细粉a与b,水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,冷却定型制成类弹头状栓剂;所述基质选自:半合成脂肪酸甘油酯、泊洛沙姆、聚乙二醇、羊毛脂中的一种或多种。
10.根据权利要求1~3所述治疗慢性乙型肝炎的中药制剂,其特征在于,所述中药制剂的剂型为:水煎灌肠剂、片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、丹剂、溶液剂、注射剂、栓剂、硬膏剂、糖浆剂或栓剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105952830A CN102058715B (zh) | 2010-12-20 | 2010-12-20 | 一种治疗慢性前列腺炎的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105952830A CN102058715B (zh) | 2010-12-20 | 2010-12-20 | 一种治疗慢性前列腺炎的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102058715A true CN102058715A (zh) | 2011-05-18 |
CN102058715B CN102058715B (zh) | 2012-06-06 |
Family
ID=43994340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105952830A Expired - Fee Related CN102058715B (zh) | 2010-12-20 | 2010-12-20 | 一种治疗慢性前列腺炎的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102058715B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102872415A (zh) * | 2012-09-11 | 2013-01-16 | 宋连花 | 一种治疗慢性前列腺炎的中药灌肠剂 |
CN102988675A (zh) * | 2012-12-28 | 2013-03-27 | 青岛华仁信息技术开发有限公司 | 一种治疗慢性前列腺炎的中药组合物及其制备方法 |
CN103432270A (zh) * | 2013-07-31 | 2013-12-11 | 唐国萍 | 一种治疗慢性前列腺炎的中药组合物 |
CN104784380A (zh) * | 2015-04-30 | 2015-07-22 | 河南中医学院 | 一种治疗良性前列腺增生及慢性前列腺炎排尿不适的灌肠祛瘀通闭中药汤 |
CN104888183A (zh) * | 2015-06-16 | 2015-09-09 | 郑相国 | 养生保健中成药 |
CN109106881A (zh) * | 2017-06-23 | 2019-01-01 | 梁根娣 | 一种治疗慢性前列腺炎的中药组合物及其制备工艺 |
CN110151971A (zh) * | 2018-07-11 | 2019-08-23 | 江苏万可瑞科技实业有限公司 | 一种用于治疗男性前列腺炎的凝胶及其生产方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679686A (zh) * | 2005-02-02 | 2005-10-12 | 姚素英 | 一种治疗前列腺疾病胶囊 |
CN1895463A (zh) * | 2006-06-30 | 2007-01-17 | 王连喜 | 一种治疗前列腺疾病中药制剂及其制备方法 |
-
2010
- 2010-12-20 CN CN2010105952830A patent/CN102058715B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679686A (zh) * | 2005-02-02 | 2005-10-12 | 姚素英 | 一种治疗前列腺疾病胶囊 |
CN1895463A (zh) * | 2006-06-30 | 2007-01-17 | 王连喜 | 一种治疗前列腺疾病中药制剂及其制备方法 |
Non-Patent Citations (1)
Title |
---|
《中华男科学》 20021030 曾庆琪等 2002年中华中医药学会男科学学术大会纪要 388-390 1-10 第08卷, 第05期 2 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102872415A (zh) * | 2012-09-11 | 2013-01-16 | 宋连花 | 一种治疗慢性前列腺炎的中药灌肠剂 |
CN102872415B (zh) * | 2012-09-11 | 2014-01-29 | 宋连花 | 一种治疗慢性前列腺炎的中药灌肠剂 |
CN102988675A (zh) * | 2012-12-28 | 2013-03-27 | 青岛华仁信息技术开发有限公司 | 一种治疗慢性前列腺炎的中药组合物及其制备方法 |
CN102988675B (zh) * | 2012-12-28 | 2014-04-23 | 徐桂丽 | 一种治疗慢性前列腺炎的中药组合物及其制备方法 |
CN103432270A (zh) * | 2013-07-31 | 2013-12-11 | 唐国萍 | 一种治疗慢性前列腺炎的中药组合物 |
CN104784380A (zh) * | 2015-04-30 | 2015-07-22 | 河南中医学院 | 一种治疗良性前列腺增生及慢性前列腺炎排尿不适的灌肠祛瘀通闭中药汤 |
CN104784380B (zh) * | 2015-04-30 | 2018-10-02 | 河南中医学院 | 一种治疗良性前列腺增生及慢性前列腺炎排尿不适的灌肠祛瘀通闭中药汤 |
CN104888183A (zh) * | 2015-06-16 | 2015-09-09 | 郑相国 | 养生保健中成药 |
CN109106881A (zh) * | 2017-06-23 | 2019-01-01 | 梁根娣 | 一种治疗慢性前列腺炎的中药组合物及其制备工艺 |
CN110151971A (zh) * | 2018-07-11 | 2019-08-23 | 江苏万可瑞科技实业有限公司 | 一种用于治疗男性前列腺炎的凝胶及其生产方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102058715B (zh) | 2012-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102145064B (zh) | 一种治疗老年性阴道炎的中药组合物及其制备方法 | |
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN105343625A (zh) | 一种排毒除湿利胆的蒲公英口服液及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN102058715B (zh) | 一种治疗慢性前列腺炎的中药制剂及其制备方法 | |
CN102178804B (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
CN102145111A (zh) | 一种治疗霉菌性阴道炎的中药组合物及其制备方法 | |
CN102178814B (zh) | 一种治疗滴虫性阴道炎的中药组合物及其制备方法 | |
CN103169881A (zh) | 一种补充妇女绝经期雌激素的中药保健品及其制备方法 | |
CN103041208B (zh) | 一种治疗妇女更年期综合征的中药制剂及其制备方法 | |
CN101607051B (zh) | 一种中药减肥组合物及其制备方法 | |
CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
CN102988675B (zh) | 一种治疗慢性前列腺炎的中药组合物及其制备方法 | |
CN101507776B (zh) | 一种治疗肾虚、腰膝酸软的中药制剂及其制备方法 | |
CN103316245B (zh) | 一种治疗小儿遗尿的中药制剂及其制备方法 | |
CN103041262B (zh) | 一种治疗慢性前列腺炎的中药灌肠剂及其制备方法 | |
CN104274754A (zh) | 一种治疗小儿遗尿的中药组合物及其制备方法 | |
CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
CN105412697A (zh) | 一种清热除湿、保肝利胆的佩兰口服液及其制备方法 | |
CN103041263B (zh) | 一种治疗慢性前列腺炎的中药直肠给药栓剂及其制备方法 | |
CN105233056A (zh) | 一种清热除湿、利胆排毒的大黄口服液及其制备方法 | |
CN105106696A (zh) | 一种治疗慢性前列腺炎的中药组合物 | |
CN103520643A (zh) | 一种用于治疗糖尿病白内障的中药制剂及其制备方法 | |
CN103054991A (zh) | 一种治疗少腹部不适的中药组合物及其制备方法和用途 | |
CN105288315A (zh) | 一种清热除湿、利胆排毒的金钱草口服液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120606 Termination date: 20121220 |